Iovance Biotherapeutics, Inc.IOVANASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank92
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P92
Near historical high
vs 2Y Ago
247.1x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
PeriodValue
Q4 202533.21%
Q3 2025-16.69%
Q2 202534.96%
Q1 2025-41.47%
Q4 2024-24.29%
Q3 202440.09%
Q2 202419.50%
Q1 2024-45.62%
Q4 20230.13%
Q3 202310.50%
Q2 20235.87%
Q1 2023-28.51%
Q4 2022-22.03%
Q3 202218.02%
Q2 2022-5.19%
Q1 2022-37.05%
Q4 20216.66%
Q3 2021-6.82%
Q2 202113.44%
Q1 20210.48%
Q4 2020-54.74%
Q3 2020-10.59%
Q2 202043.89%
Q1 2020-21.31%
Q4 2019-27.59%
Q3 2019-24.82%
Q2 2019-16.17%
Q1 20197.79%
Q4 2018-12.97%
Q3 2018-16.74%
Q2 2018-34.03%
Q1 201814.86%
Q4 20172.25%
Q3 2017-22.58%
Q2 20176.95%
Q1 2017-54.64%
Q4 20160.41%
Q3 2016-225.75%
Q2 201617.66%
Q1 201630.81%